What are the recommended diagnostic evaluations and initial treatment strategies for thrombotic microangiopathy in children?

TMA in Children: Diagnostic Evaluation and Initial Treatment

For children with suspected thrombotic microangiopathy, immediately confirm the diagnosis with evidence of microangiopathic hemolytic anemia (elevated LDH, indirect bilirubin, reticulocytes, schistocytes on blood smear, negative Coombs) plus thrombocytopenia, then rapidly initiate diagnostic workup to differentiate between Shiga toxin-producing E. coli HUS, complement-mediated TMA, and secondary causes, as this distinction determines whether supportive care alone versus complement inhibition therapy is required 1, 2.

Diagnostic Approach

Step 1: Syndromic Confirmation

Confirm TMA syndrome by documenting:

• Microangiopathic hemolytic anemia: Elevated reticulocytes, LDH, and indirect bilirubin with negative direct Coombs test and schistocytes on peripheral blood smear 3
• Thrombocytopenia not explained by other causes
• End-organ damage, particularly renal involvement (elevated creatinine, proteinuria, hematuria)

Step 2: Immediate Laboratory Evaluation (Before Any Treatment)

Critical samples must be obtained before plasma exchange or complement inhibition 2, 3:

• ADAMTS13 activity and inhibitor - to rule out thrombotic thrombocytopenic purpura (TTP)
• Complement studies: C3, C4, CH50, factor H, factor I, and soluble C5b-9 (sC5b-9)
• Stool culture for Shiga toxin-producing E. coli and Shiga toxin PCR
• Streptococcus pneumoniae testing (blood culture, urine antigen)
• Genetic testing panel for complement genes (CFH, CFI, CFB, C3, MCP, THBD, DGKE) 1, 2

Step 3: Etiologic Classification

Shiga toxin-producing E. coli HUS (most common in children):

• Prodrome of bloody diarrhea
• Positive stool Shiga toxin
• Supportive care only; do not use antibiotics or antimotility agents 1, 2

Streptococcus pneumoniae-associated HUS:

• Evidence of invasive S. pneumoniae infection
• Positive Coombs test (T-antigen activation)
• Avoid plasma products as they contain anti-T antibodies 1

Complement-mediated (atypical) HUS:

• Absence of Shiga toxin or S. pneumoniae
• Often genetic complement abnormalities (found in ~60% when tested) 1, 4
• Requires urgent complement inhibition therapy

Secondary TMA:

• Associated with transplantation, malignancy, drugs (calcineurin inhibitors, chemotherapy), autoimmune disease, or malignant hypertension 1, 5
• May have underlying complement abnormalities in up to 44% of cases 4

Initial Treatment Strategy

For Suspected Complement-Mediated TMA

Initiate eculizumab immediately while awaiting confirmatory testing 1, 2:

• Do not delay treatment for genetic results
• Ensure meningococcal vaccination (or prophylactic antibiotics if unable to vaccinate immediately)
• Therapeutic drug monitoring may optimize dosing 6

For Transplant-Associated TMA

Use the "Three-Hit Hypothesis" treatment algorithm 5:

1. Remove triggers: Discontinue calcineurin inhibitors, treat infections, manage GVHD
2. Address drivers: Consider complement inhibition, especially if genetic testing reveals complement abnormalities
3. Supportive care: Blood pressure control, avoid nephrotoxins

For Shiga Toxin-Associated HUS

• Supportive care only: Fluid management, electrolyte correction, dialysis if needed
• Monitor for complications (seizures, bowel perforation)
• Approximately two-thirds improve spontaneously 1, 2

Critical Pitfalls to Avoid

Do not confuse TMA with ITP: The provided ITP guidelines 7, 8, 7, 8 are irrelevant to TMA management. TMA requires thrombocytopenia PLUS microangiopathic hemolytic anemia PLUS organ damage, whereas ITP is isolated thrombocytopenia.

Do not delay complement inhibition in atypical HUS: Permanent renal damage occurs rapidly. Start eculizumab empirically if complement-mediated TMA is suspected 1, 5.

Do not use plasma exchange as first-line in children: Unlike adults with TTP, most pediatric TMA is either Shiga toxin-associated (requiring supportive care only) or complement-mediated (requiring complement inhibition, not plasma exchange) 1, 2.

Obtain genetic testing in all cases: Even "secondary" TMAs may have underlying complement abnormalities that increase recurrence risk and require long-term complement inhibition 4, 9.

Admission and Monitoring

• ICU admission for severe cases with neurological involvement, severe renal failure, or cardiovascular instability 3
• Daily monitoring of hemoglobin, platelets, LDH, creatinine, and blood pressure
• Serial complement levels if on complement inhibition therapy

The distinction between etiologies is critical because treatment differs fundamentally: supportive care for Shiga toxin HUS versus complement inhibition for atypical HUS versus trigger removal for secondary TMA 1, 2.